-
公开(公告)号:US20240366598A1
公开(公告)日:2024-11-07
申请号:US18634154
申请日:2024-04-12
Applicant: Pfizer Inc.
Inventor: Kevin James Filipski , Matthew Forrest Sammons , Samuel Michael Levi , Yang Wang , Advaita Panchagnula , Yanfei Guan , Matthew Richard Reese , Luis Angel Martinez Alsina , Steven Victor O'Neil , Lei Zhang , Qifang Li , Ethan Lawrence Fisher , Danica Antonia Rankic
IPC: A61K31/506 , A61K31/403 , A61K31/4439 , A61K31/444 , A61P3/04 , C07D207/16 , C07D209/52 , C07D401/12 , C07D401/14 , C07D403/12
Abstract: Described herein are compounds of Formula I: and their pharmaceutically acceptable salts, wherein R1, R2, R3, L1, T1, T2, T3, T4, t1, and t2 are defined herein; their use as GIPR antagonists; pharmaceutical compositions containing such compounds and salts; and the use of such compounds and salts to treat or prevent, for example, obesity, weight gain, and/or T2DM.
-
公开(公告)号:US20240150334A1
公开(公告)日:2024-05-09
申请号:US18482129
申请日:2023-10-06
Applicant: Pfizer Inc.
Inventor: Jan Antoinette Cusi Romero Adams , Bruce Michael Bechle , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Deane Milford Nason, II , Steven Victor O'Neil , Danica Antonia Rankic , Yang Wang , Ann Sorrentino Wright , Lei Zhang , Liying Zhang , David James Edmonds
IPC: C07D413/04 , C07D231/56 , C07D263/56 , C07D401/04 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D498/04 , C07D513/04
CPC classification number: C07D413/04 , C07D231/56 , C07D263/56 , C07D401/04 , C07D403/04 , C07D405/14 , C07D413/14 , C07D417/04 , C07D471/04 , C07D487/04 , C07D491/048 , C07D498/04 , C07D513/04
Abstract: Described herein are compounds of Formula I,
wherein the variables are defined herein, their use as HSD17B13 inhibitors and/or degraders, pharmaceutical compositions containing such compounds and their use to treat, for example, NAFLD and NASH.-
公开(公告)号:US20240238425A1
公开(公告)日:2024-07-18
申请号:US18541015
申请日:2023-12-15
Applicant: Pfizer Inc.
Inventor: Jan Antoinette Cusi Romero Adams , Yotam Ashkenazi , Matthew Frank Brown , Jason Kenneth Dutra , Michelle Renee Garnsey , Xinjun Hou , Jisun Lee , Yajing Lian , Deane Milford Nason, II , Steven Victor O'Neil , Amanda Brooke Pecora , Alistair Dean Richardson , Matthew Forrest Sammons , Yang Wang , Ann Sorrentino Wright , Jun Xiao , Lei Zhang , Liying Zhang
Abstract: Described herein are 3-fluoro-4-hydroxybenzamide-containing inhibitors and/or degraders, and pharmaceutical compositions containing 3-fluoro-hydroxybenzamide-containing inhibitors and/or degraders. In some embodiments, the 3-fluoro-4-hydroxybenzamide-containing compounds of the disclosure can be used to treat a condition, for example, nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
-
-